I want to invest

Oxygen Biotech s.r.o. is an American biotechnology company with Czech roots that has the potential to reduce mortality caused by the severe course of COVID-19 thanks to our technology.

It does this by addressing acute respiratory distress syndrome (ARDS). The active ingredient is so-called bazedoxifene, which inhibits the signalling of the main trigger of the immune system's overreaction, the so-called cytokine storm.
CUIP has negotiated the sale of the research drug technology developed by the team of the 1st Faculty of Medicine and Faculty of Science of Charles University working at the specialised BIOCEV facility.

GeneSpector Innovations (GSIN) brings together university research teams from different disciplines and, with the direct or indirect involvement of global commercial partners, translates their discoveries and approaches into marketable products and solutions.

The spin-off company GSIN, founded by three Czech entities, with Charles University holding the largest share, builds on its successful predecessor, GeneSpector. The latter launched a comprehensive certified PCR testing solution during the COVID-19 pandemic and achieved EBITDA of 40% in its first 18 months of operation. It thus became the most successful startup in the CEE region during that period.
In collaboration with CUIP, GSIN is developing strategic partnerships in bioseparation and other technologies or applications across biomedical, pharmaceutical and other related fields.

Company GlobeTech Innovation has founded SAIN, a premium cosmetic brand built on technology from the 1st Medical Faculty of Charles University's BIOCEV facility. The main active ingredient of the product is alaptide molecule, which affects the physiological regenerative abilities of the skin.

The currently available product is a cosmeceutical range of premium creams, but the development does not end there. The next milestone is obtaining the necessary certification for the use of the technology in healthcare.
CUIP secured the transfer of part of the intellectual property to GlobeTech Innovation. The CUIP team has participated in extensive media coverage and continues to collaborate to develop the technology for medical use.